![Martine Zimmermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martine Zimmermann
Director/Board Member at
CANDEL THERAPEUTICS, INC.
Net worth: 1 M $ as of 30/08/2026
Profile
Dr. Martine Zimmermann is an Independent Director at Candel Therapeutics, Inc., an Independent Director at Ligand Pharmaceuticals, Inc. and an EVP-Regulatory Affairs & Quality Assurance at Inventiva SA. She is on the Board of Directors at Candel Therapeutics, Inc. and Ligand Pharmaceuticals, Inc. Dr. Zimmermann was previously employed as a SVP, Head-Regulatory Affairs, R&D Quality by Ipsen Biopharmaceuticals, Inc. and a Senior VP & Head-Global Regulatory Affairs by Alexion Pharmaceuticals, Inc. She also served on the board at Caelum Biosciences, Inc. She received her doctorate degree from the University of Strasbourg and a doctorate degree from Louis Pasteur University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 04/06/2026 | 5,097 ( 0.03% ) | 1 M $ | 30/08/2026 | |
| 07/09/2026 | 0 ( -.--% ) | - $ | 30/08/2026 |
Martine Zimmermann active positions
| Companies | Position | Start |
|---|---|---|
| INVENTIVA | General Counsel | 08/07/2025 |
| LIGAND PHARMACEUTICALS INCORPORATED | Director/Board Member | 25/09/2023 |
| CANDEL THERAPEUTICS, INC. | Director/Board Member | 07/09/2026 |
Former positions of Martine Zimmermann
| Companies | Position | End |
|---|---|---|
Ipsen Biopharmaceuticals, Inc.
 Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | General Counsel | 31/07/2025 |
| ALEXION PHARMACEUTICALS, INC. | General Counsel | 31/01/2023 |
Caelum Biosciences, Inc.
 Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Director/Board Member | 31/12/2020 |
Training of Martine Zimmermann
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
67
1st degree connections
8
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Ligand Pharmaceuticals, Inc.
 Ligand Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and sells drug development technologies | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
University of Strasbourg
 University of Strasbourg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Candel Therapeutics, Inc.
 Candel Therapeutics, Inc. BiotechnologyHealth Technology Develops and distributes immunotherapies for the treatment of cancer | Health Technology |
Ipsen Biopharmaceuticals, Inc.
Ipsen Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as biopharmaceutical company | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Caelum Biosciences, Inc.
Caelum Biosciences, Inc. BiotechnologyHealth Technology Operates as clinical stage biotechnology company that develops treatments for AL amyloidosis, rare and life-threatening hematologic disorders | Health Technology |
Louis Pasteur University
 Louis Pasteur University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Martine Zimmermann
